002720 — Kukje Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapContrarian

Annual income statement for Kukje Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	130,395	119,746	126,583	135,373	156,463
Cost of Revenue
Gross Profit	64,805	54,470	63,254	67,225	82,495
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	124,322	121,425	121,787	139,229	149,787
Operating Profit	6,073	-1,679	4,797	-3,856	6,676
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,594	-1,110	4,745	-6,681	6,609
Provision for Income Taxes
Net Income After Taxes	2,195	-1,556	3,543	-8,415	5,206
Minority Interest
Net Income Before Extraordinary Items
Net Income	2,203	-1,559	3,557	-8,415	5,205
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,203	-1,559	3,557	-8,415	5,205
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	99.8	-76.6	193	-365	253
Dividends per Share